Tumor cell-expressed PD-L1 binds to the PD-1 receptor on CD8+ T lymphocytes, thereby inhibiting the activity of effector T cells, which weakens the anti-tumor activity of the immune system [38]. The gene discussed is CD8A; the disease is neoplasm.